Skandinaviska Enskilda Banken Ab (Publ) Bicycle Therapeutics PLC Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.5 Billion
- Q3 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 42,729 shares of BCYC stock, worth $877,653. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,729
Previous 42,729
-0.0%
Holding current value
$877,653
Previous $864,000
12.15%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BCYC
# of Institutions
112Shares Held
41.2MCall Options Held
39.6KPut Options Held
24.6K-
Baker Bros. Advisors LP New York, NY9.4MShares$193 Million2.28% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.55MShares$72.9 Million2.97% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.34MShares$48.1 Million9.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$46.3 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY1.96MShares$40.2 Million0.74% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $610M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...